Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 13/20 | 0.49 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13481169 | 0.89 | AR (0.49) | ARMBOAT4SLC22A12GPR3 | |
| SCHEMBL22199041 | 0.84 | AR (0.55) | ARSLC22A12GPR3 | |
| SCHEMBL16342267 | 0.84 | AR (0.43) | ARKDM4EUSP2ALDH1A1 | |
| SCHEMBL16952374 | 0.82 | GPR3 (0.38) | ARMBOAT4ALDH1A1GPR3 | |
| SCHEMBL23753793 | 0.80 | AR (0.50) | ARMBOAT4GRM2KDM4EUSP2 | |
| SCHEMBL29846977 | 0.80 | AR (0.50) | ARMBOAT4GRM2KDM4EUSP2 | |
| SCHEMBL7138076 | 0.79 | AR (0.42) | ARMBOAT4GRM2KDM4EUSP2 | |
| SCHEMBL25762038 | 0.79 | AR (0.42) | ARMBOAT4GRM2KDM4EUSP2 | |
| SCHEMBL15969048 | 0.79 | MAOB (0.42) | ARMBOAT4GRM2KDM4EUSP2 | |
| SCHEMBL21239555 | 0.79 | KDM4E (0.61) | ARMBOAT4GRM2KDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023023527-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-20200235304-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | LG CHEM, LTD. (KR) | 2020-07-23 | — | — | US | disclosed |
| WO-2019078620-A1 | NOVEL COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE USING SAME | 주식회사 엘지화학 | 2019-04-25 | — | — | WO | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| WO-2003048109-A1 | NOVEL GLUCAGON ANTAGONISTS | NOVO NORDISK A/S (DK) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200235304-A1 | NOVEL COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME | C1S, CBR3, CCNL2 | AR 292/4885MBOAT4 4293/4885GRM2 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.